Shrestha Ashish C, Wijesundara Danushka K, Masavuli Makutiro G, Mekonnen Zelalem A, Gowans Eric J, Grubor-Bauk Branka
Virology Laboratory, Discipline of Surgery, Basil Hetzel Institute for Translational Health Research and University of Adelaide, Adelaide 5011, Australia.
Vaccines (Basel). 2019 Apr 30;7(2):38. doi: 10.3390/vaccines7020038.
DNA vaccines present one of the most cost-effective platforms to develop global vaccines, which have been tested for nearly three decades in preclinical and clinical settings with some success in the clinic. However, one of the major challenges for the development of DNA vaccines is their poor immunogenicity in humans, which has led to refinements in DNA delivery, dosage in prime/boost regimens and the inclusion of adjuvants to enhance their immunogenicity. In this review, we focus on adjuvants that can enhance the immunogenicity of DNA encoded antigens and highlight the development of a novel cytolytic DNA platform encoding a truncated mouse perforin. The application of this innovative DNA technology has considerable potential in the development of effective vaccines.
DNA疫苗是开发全球疫苗最具成本效益的平台之一，在临床前和临床环境中已经进行了近三十年的测试，并在临床上取得了一些成功。然而，DNA疫苗开发的主要挑战之一是其在人类中的免疫原性较差，这导致了在DNA递送、初免/加强免疫方案中的剂量以及添加佐剂以增强其免疫原性方面的改进。在本综述中，我们重点关注可增强DNA编码抗原免疫原性的佐剂，并强调一种编码截短型小鼠穿孔素的新型溶细胞DNA平台的开发。这种创新DNA技术的应用在有效疫苗的开发中具有相当大的潜力。
